An expert perspective from Ann Lambrix, Executive Director, RCM Consulting on the evolving multiplex molecular reimbursement landscape and what laboratories should be preparing for · In partnership with Applied BioCode
In a recent webinar hosted by Applied BioCode, reimbursement expert Ann Lambrix covered the key reimbursement considerations that every laboratory performing multiplex molecular panel testing should understand:
- Why multiplex molecular panel claims are facing increased denial rates and how the payer landscape has evolved.
- What MolDx compliance requires beyond obtaining a Z-code and the documentation your lab needs to support reimbursement.
- The six most common reasons multiplex panel claims are denied and practical strategies to address each one before submission. How to build a front-end denial prevention workflow that helps protect revenue and reduce avoidable denials.
- Optimize reimbursement through targeted performance insights.
- Improve financial outcomes with proactive, data-driven decision-making
Clinical laboratory directors and billing teams today are inundated with denied claims, write-offs, appeal volumes, and payment variances, yet many still struggle to translate that information into meaningful action.
Denials now account for approximately 11% of all submitted claims. For an average health system, that can translate into more than 100,000 unpaid claims annually. The line between reactive firefighting and proactive denial prevention often comes down to which metrics are prioritized, how they are interpreted, and whether teams are aligned in using them to drive operational change.
Scientific innovation in molecular diagnostics has significantly outpaced payer policy development. Today’s multiplex panels can simultaneously detect 17 or more pathogens from a single patient sample, delivering rapid, clinically actionable insights that directly influence treatment decisions. However, reimbursement frameworks have not evolved at the same pace, leaving laboratories to navigate uncertainty, shifting coverage rules, and increasing financial exposure.
“The science is typically at least five to ten years ahead of the payers. Labs continue to develop innovative tests that enable physicians to detect disease more quickly and make better-informed treatment decisions. However, payer policies – particularly for multiplex testing – have struggled to keep pace with these advances.”
Ann Lambrix, MSJ
This blog focuses on the regulatory developments laboratories need to be actively monitoring and what steps to take now to remain financially protected in this rapidly shifting environment.
“Labs are currently facing a rapidly changing reimbursement landscape. Tests that were historically considered payable and reimbursed without issue for many years are now increasingly being denied. Many laboratories that had previously experienced consistent payment are suddenly receiving denials, documentation requests from payers, or clawback demands for claims that had already been paid.”
Ann Lambrix, MSJ
What’s Coming on the Regulatory Horizon?
Three regulatory developments deserve close attention from every laboratory running multiplex molecular panels.
PAMA. The Protecting Access to Medicare Act reporting requirement is now active. If your laboratory billed during the data collection period of January 1 – June 30, 2025 and meets the applicable laboratory definition, you are required to report your private payer data by July 31, 2026. Medicare uses this data to set the Clinical Laboratory Fee Schedule, and laboratories should anticipate significant rate adjustments effective approximately 2027. Laboratories with managed care contracts tied to CLFS rates need to be modeling that impact now.
LDT oversight. The FDA’s rule on laboratory-developed test oversight was rescinded, but that does not resolve the underlying payer concern about LDTs. Payers are incorporating LDT-specific scrutiny into their coverage policies more stringent technical assessment requirements, more restrictive coverage language for non-FDA-cleared tests. The compliance burden has not decreased.
The trajectory of the non-MolDx MACs. The absence of formal policy in Novitas, First Coast, and NGS jurisdictions is not sustainable given current utilization levels. More structure is coming whether through MolDx expansion or independent LCD development. Laboratories billing in those jurisdictions should be operating to MolDx-level standards now, not waiting for a formal requirement.
The Path Forward for Molecular Diagnostics Reimbursement
Sustainable reimbursement success in multiplex molecular diagnostics requires a proactive, integrated operational strategy, not a one-time compliance initiative. Laboratories must establish payer-aligned workflows, maintain robust documentation systems that support accurate claims submission and first-pass adjudication, develop expertise in molecular diagnostic coding and billing, and continuously monitor evolving payer policies and coverage requirements.
The laboratories best positioned to succeed in this increasingly complex reimbursement landscape will be those that embed these capabilities into their routine operations, rather than responding only after claim denials or payment challenges arise.
Watch the Full Webinar
The full recording including extended Q&A is available: link
Reimbursement consulting inquiries: ann.lambrix@lighthouselabservices.com
Learn more about BioCode® multiplex panels: link
Ann Lambrix
Executive Director, RCM Consulting.
Ann Lambrix serves as Lighthouse’s Executive Director of RCM Consulting, heading up the division’s day-to-day operations. With more than 23 years in the medical insurance and billing industry, her experience provides for an insightful analysis of revenue cycle and the payor trends impacting reimbursement. Additionally, Ann holds a MSJ in Health and Hospital Law.